Tyme Technologies — Investor Presentation (November 2018)
23 slides from Tyme Technologies's investor presentation, Nov 13, 2018
Slide 1: Tyme Technologies November 2018
Tyme Logicum | Scientia | Humanitas November 2018 NASDAQ: TYME Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk fac
Slide 3: Tyme Technologies, Inc. Corporate Overview
Tyme Technologies, Inc. Corporate Overview (NASDAQ: TYME) SM-88 SM-88 (our lead oral product) has shown anti-tumor activity across 15 hematologic and solid cancers Two monotherapy Phase II studies for prostate and pancreatic cancer ongoing Two pivotal cohorts in pancreatic cancer expected to begin d
Slide 4: Development Pipeline
Development Pipeline *Investigator-initiated trial GA = gemcitabine/Abraxane®️, IND = Investigational New Drug Application ECOG PS = Eastern Cooperative Oncology Group Performance Status Program Formulation Cancer Indication Pre-IND Phase I Phase II Phase II/III SM-88 Oral Pancreatic: 2L+, ECOG 0-2
Slide 5: Targeting Cancer's Unique Metabolism
Targeting Cancer’s Unique Metabolism Nearly all cancers exhibit the Warburg Effect and have abnormal uptake of tyrosine SM-88 uses this pathway to enter cancer and disrupt protein synthesis To enhance the tyrosine’s effect, SM-88 is administered with microdoses of three other drugs: Rapamycin (0.5mg
Slide 6: Clinical Evidence of SM-88 Mechanism: PET Imaging
Clinical Evidence of SM-88 Mechanism PET Imaging Illustrates SM-88 Response 8/9 (86%) subjects with initial PET1-based responses went on to have future CT1-based responses Interruption of cancer cell metabolism vs. broad cytotoxic effects of chemotherapy Tumor inflammation / immune response could be
Slide 7: Clinical Evidence of SM-88 Mechanism: Interim Prostate Data
Clinical Evidence of SM-88 Mechanism Interim Data from Ongoing Phase Ib/II Prostate Trial Circulating Tumor Cells as a Surrogate Biomarker CTCs linked to prognosis and progression in prostate, breast and other cancers Selectivity of Uptake with Cancer Cells Selective uptake should be reflected by mi
Slide 8: First Human Study: Overall Survival and Response
Overall Survival (months) RECIST Designation1 Median OS of 29.8 Months First Human Study (FHS): 33% RECIST ORR, 29.8 month Overall Survival 90% of patients experienced clinical benefit (CR, PR or SD)2 33% ORR; Four CR, six PR 17 SD (57%) with a median OS of nearly 30 months Tumor assessments confirm
Slide 9: Safety Profile: First Human Study
Safety Profile: First Human Study No Grade 3-4 drug related adverse events observed in the First Human Study Median Improvement of 1.0 point on the ECOG PS from baseline to post first 6-week cycle 1. Includes all adverse events deemed as possibly, probably or definitely drug-related. 2. Generally tr
Slide 10: Pancreatic Treatment Paradigm
Pancreatic Treatment Paradigm Diagnosed (U.S.) 55,440 41,234 Receive 1st Line: 21,830 Receive 2ndLine: 10,187 Receive 3rd Line: # of Patients Gemzar® / Abraxane® (“GA”); or FOLFIRINOX Single agent (ECOG 2) Onivyde® +5FU/LV (GA-failed) GA (5FU-failed) Single agent (ECOG 2) “No data are available to r
Slide 11: Historical Trial Outcomes in 2nd Line or Later Pancreatic Cancer
Historical Trial Outcomes in 2nd Line or Later Pancreatic Cancer Arm N ORR Median Months 2L PFS 2L OS OS post 2L PFS NAPOLI-1 Onivyde+5FU/LV 117 7.7% 3.1 6.1 3.0 5FU/LV 119 0.8% 1.5 4.2 2.7 Onivyde alone 151 3.3% 2.7 4.9 1.2 Median of 15 other 2L+ pancreatic trials* 40 (30-168) 10.0% (0-23%) 2.3 (1.
Slide 12: Why are Pancreatic Cancer Outcomes so Poor?
Why are Pancreatic Cancer Outcomes so Poor? Dense stroma prevents many molecules from reaching the tumor As a result, pancreatic cancer is treated through a combination of highly toxic chemotherapies to try to both break down the surrounding barriers and kill the tumor cells Tumor Stroma / Fibrosis
Slide 13: Previous SM-88 Data for Pancreatic Cancer
Example Monotherapy RECIST Response BASELINE POST 10 WEEKS THERAPY Previous SM-88 Data for Pancreatic Cancer Subject Baseline ECOG Previous Treatments* BORR PFS (mth) OS (mth) Monotherapy 084 DO 2-3 S CR 13 15 031 JP 2-3 C(1) PR 4 4** 037 DP 0-1 S, R, C(1) SD 8 45 018 DD 1 S SD 24 24 047 FC 1 C(1) S
Slide 14: SM-88 First Therapy Selected for Precision Promise Pivotal Trial
SM-88 First Therapy Selected for Precision Promise Pivotal Trial Selected to include two SM-88 treatment arms Monotherapy in 2L Combination with GA in both 1L & 2L Monotherapy arm will be first arm submitted to FDA with PP master protocol IND Enrollment expected to begin 1H19 Arm Selection Committee
Slide 15: Why Join a Platform Trial?
Why Join a Platform Trial? Precision Promise Pivotal Trial “I personally believe that the clinical trial system is broken and that master protocols, trial platforms and clinical trial networks need to be the future” - Janet Woodcock, Director of CDER, September 2017 Accelerate Approval Survival endp
Slide 16: Who is PanCAN?
Who is PanCAN? One of the largest organizations focused exclusively on pancreatic cancer ~$35m annual operating budget with more than 150 employees Overarching goal to double pancreatic cancer survival rates by 2020 Driving research, government advocacy, patient services and community engagement in
Slide 17: Impact on Existing Tyme's Pancreatic Program
Impact on Existing Tyme’s Pancreatic Program SM-88 may have additional regulatory pathways beyond Precision Promise 3rd Line+: No existing standard of care because the two standard pancreatic backbone therapies (gemcitabine and 5FU) would have already failed SM-88 has a novel mechanism that does not
Slide 18: Phase II Trial (TYME-88-PANC): Metastatic Pancreatic Cancer
Phase II Trial (TYME-88-PANC): Metastatic Pancreatic Cancer INDICATION SM-88 Monotherapy in Refractory Metastatic Pancreatic Cancer Patients (2nd Line+; ECOG PS 0-2) ~81 pts Structure: Open-Label Sites: ~35 across North America End Points: Response Rate, OS, and PFS CRO: Quintiles/Novella (first sit
Slide 19: Proof of Concept Trials: SM-88 Opportunity
Proof of Concept Trials SM-88 Opportunity Cancers with Demonstrated Responses to SM-88 Pancreatic Breast Ovarian Prostate Colon Glioma/Glioblastoma Ewings Sarcoma Renal Appendix Soft-Tissue Sarcoma Thyroid Hodgkins Lymphoma Lung Head & Neck (SCCHN) Non-Hodgkin’s Lymphoma Phase Ib/II Prostate (Mainte
Slide 20: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Preclinical animal data with SM-88 Initial results expected by YE18 Planned analysis of Phase II pancreatic cancer trial Interim Data expected in January 2019 Update for Phase Ib/II prostate cancer trial Update expected during 1Q19 Initiate Precision Promise monothera
Slide 21: Management, Board, and Advisors
Management, Board, and Advisors FOUNDERS Steve Hoffman Chairman, CEO & CSO Michael Demurjian Director & COO OTHER EXECUTIVES Ben Taylor President & CFO Dr. Giuseppe Del Priore Chief Medical Officer Jon Eckard, PhD Chief Scientific Affairs Officer Michele Korfin Chief Commercial Officer Shabnam Stani
Slide 22: 2018 YTD Achievements
2018 YTD Achievements Presented data on SM-88 in pancreatic cancer (ASCO GI) and interim results from Phase II trial in prostate cancer (ASCO GU) Completed a common stock offering in March 2018 Completed Stage 1 enrollment of Phase II trial in metastatic pancreatic cancer in September; data expected
Slide 23: State Street 7™ FLOOR
17 State Street 7™ FLOOR NEW YORK, NY 10004 NASDAQ: TYME INFO@TYMEINC.COM TYMEINC.COM
Tyme Technologies — Investor Presentation (November 2018) on 6ix